The department of urology at the University of Montreal, chaired by Prof. Saad, for many years has predominantly been treating prostate cancers and in particular those that evolve in bone metastases. For this reason it has participated in all major trials for the study of drugs for the treatment of metastatic patients, including the latest, based on the administration of Radium 233. According to the outcome of the study, the compound improves survival and reduces bone and spinal complications.
The department of urology at the University of Montreal, chaired by Prof. Saad, for many years has predominantly been treating prostate cancers and in particular those that evolve in bone metastases. For this reason it has participated in all major trials for the study of drugs for the treatment of metastatic patients, including the latest, based on the administration of Radium 233. According to the outcome of the study, the compound improves survival and reduces bone and spinal complications.
EAU 2016 - Overview of the 16th Annual Congress of the European Association of Urology
16th EAU Congress: topics and guidelines
Le novità nella diagnosi precoce del tumore prostatico
Proper use of PSA in early detection of prostate cancer
The range of treatments for erectile dysfunction
Trattamento della disfunzione erettile: novità e conferme
Metastatic Prostate Cancer: efficacy of Combination Therapy
Pelvic pain and appropriate therapies
Radium 233 treatment in De novo Bone Metastase
BPH LUTS: when treating patients with alpha-blockers
Localized prostate cancer: areas of greatest commitment
Detecting prostate cancer with imaging
Fighting urinary tract infections with and without antibiotics
Alpha-blockers, first line of treatment in patients with BPH LUTS
Erus: a validated way of training in robotic surgery
